Despite its promising potential, precision oncology faces several challenges. The high cost of genetic testing and sequencing remains a significant barrier. Additionally, the complexity of cancer genetics means that not all mutations are well-understood or targetable. Another issue is the variability in how different cancers with the same genetic mutations respond to treatment, necessitating more extensive clinical trials and research. Finally, ethical considerations, such as patient privacy and the interpretation of genetic data, pose ongoing challenges.
